

Tae-You Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/239047/publications.pdf>

Version: 2024-02-01

135
papers

11,204
citations

109137

35
h-index

31759

101
g-index

136
all docs

136
docs citations

136
times ranked

15534
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis. <i>Cancer Research and Treatment</i> , 2022, 54, 383-395.	1.3	4
2	Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer. <i>Molecular Oncology</i> , 2022, 16, 2396-2412.	2.1	17
3	Longitudinal monitoring of circulating tumor DNA (ctDNA) during disease course of metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2022, 40, 189-189.	0.8	1
4	EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer. <i>Oncogene</i> , 2022, 41, 2026-2038.	2.6	13
5	Hypermethylation of PDX1, EN2, and MSX1 predicts the prognosis of colorectal cancer. <i>Experimental and Molecular Medicine</i> , 2022, 54, 156-168.	3.2	13
6	Prognostic Impact of Extramural Lymphatic, Vascular, and Perineural Invasion in Stage II Colon Cancer: A Comparison With Intramural Invasion. <i>Diseases of the Colon and Rectum</i> , 2022, Publish Ahead of Print, .	0.7	2
7	Role of Dedicated Subspecialized Radiologists in Multidisciplinary Team Discussions on Lower Gastrointestinal Tract Cancers. <i>Korean Journal of Radiology</i> , 2022, 23, .	1.5	1
8	Phenotype-based single cell sequencing identifies diverse genetic subclones in CD133 positive cancer stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 558, 209-215.	1.0	3
9	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2021, 27, 713-718.	3.2	27
10	Targeted next-generation sequencing-based detection of microsatellite instability in colorectal carcinomas. <i>PLoS ONE</i> , 2021, 16, e0246356.	1.1	6
11	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2021, 39, 1335-1347.	1.2	1
12	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , 2021, 125, 200-208.	2.9	22
13	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.	1.9	5
14	Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 569-577.	3.7	50
15	Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX. <i>Scientific Reports</i> , 2021, 11, 14609.	1.6	10
16	Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. <i>Scientific Reports</i> , 2021, 11, 16333.	1.6	14
17	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	0.8	257
18	Blood-Based Detection of Colorectal Cancer Using Cancer-Specific DNA Methylation Markers. <i>Diagnostics</i> , 2021, 11, 51.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 1096-1103.	1.3	9
20	Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 98-107.e1.	1.1	15
21	Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor-Immune Microenvironment in Colorectal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 870-881.	3.2	37
22	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. <i>JAMA Oncology</i> , 2020, 6, e204564.	3.4	746
23	Body mass index and body weight change during adjuvant chemotherapy in colon cancer patients: results from the AVANT trial. <i>Scientific Reports</i> , 2020, 10, 19467.	1.6	10
24	Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing. <i>PLoS ONE</i> , 2020, 15, e0232754.	1.1	19
25	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 122, 1630-1637.	2.9	472
26	Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. <i>Nature Genetics</i> , 2020, 52, 594-603.	9.4	380
27	Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4596-4596.	0.8	7
28	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 328-339.	4.5	32
29	A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or <i>POLE</i>-Mutated Metastatic or Unresectable Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1135-1144.	1.3	43
30	A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). <i>Oncologist</i> , 2019, 24, 18-e24.	1.9	25
31	Activation of WNT/catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring <i>PIK3CA</i> mutations. <i>International Journal of Cancer</i> , 2019, 144, 389-401.	2.3	48
32	Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Clinical Cancer Research</i> , 2019, 25, 6141-6147.	3.2	98
33	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 510-518.	1.3	39
34	Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3111-3123.	0.8	100
35	Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. <i>BMC Cancer</i> , 2019, 19, 421.	1.1	2
36	p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2019, 120, 797-805.	2.9	32

#	ARTICLE	IF	CITATIONS
37	Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of) Tj ETQq1 1 0.784314 rgBTJ/Overlock	1.6	10
38	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 223-239.	1.3	13
39	NFATC3&PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines. <i>Cancer Research and Treatment</i> , 2019, 51, 391-401.	1.3	13
40	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 211-222.	1.3	12
41	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1527-1539.	1.3	5
42	Reply to &Comment on &Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system&. <i>British Journal of Cancer</i> , 2018, 118, e4-e4.	2.9	0
43	A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 252.	1.1	7
44	A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 165-178.	4.2	23
45	Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. <i>Investigational New Drugs</i> , 2018, 36, 1072-1084.	1.2	32
46	Association Between <i>Fusobacterium nucleatum</i> , Pathway Mutation, and Patient Prognosis in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 3389-3395.	0.7	69
47	Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells. <i>Molecular Oncology</i> , 2018, 12, 1398-1409.	2.1	10
48	Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4078-4078.	0.8	3
49	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 164-174.	2.7	13
50	Prognostic implication of antitumor immunity measured by the neutrophil&lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 254-262.	2.7	51
51	Perceived needs for the information communication technology (ICT)-based personalized health management program, and its association with information provision, health-related quality of life (HRQOL), and decisional conflict in cancer patients. <i>Psycho-Oncology</i> , 2017, 26, 1810-1817.	1.0	9
52	Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. <i>British Journal of Cancer</i> , 2017, 116, 1012-1020.	2.9	40
53	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	6.3	3,224
54	Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. <i>Cancer</i> , 2017, 123, 3513-3523.	2.0	50

#	ARTICLE	IF	CITATIONS
55	Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 757-764.	3.3	27
56	Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 147-153.	0.6	11
57	Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. <i>Oncotarget</i> , 2017, 8, 2329-2341.	0.8	50
58	Korean Cancer Patients's Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. <i>Cancer Research and Treatment</i> , 2017, 49, 1033-1043.	1.3	19
59	Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. <i>Journal of Breast Cancer</i> , 2017, 20, 347.	0.8	13
60	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4013-4013.	0.8	76
61	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4073-4073.	0.8	133
62	Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-226.	0.8	19
63	Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 252-252.	0.8	4
64	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 454-463.	1.3	1
65	Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 416-416.	0.8	1
66	Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 460-460.	0.8	0
67	Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 454-454.	0.8	0
68	Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016, 7, 58007-58021.	0.8	63
69	Dynamic cohesin-mediated chromatin architecture controls epithelial-mesenchymal plasticity in cancer. <i>EMBO Reports</i> , 2016, 17, 1343-1359.	2.0	21
70	Src as a Therapeutic Target in Biliary Tract Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1515-1524.	1.9	10
71	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016, 16, 515.	1.1	11
72	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016, 115, 1201-1205.	2.9	19

#	ARTICLE	IF	CITATIONS
73	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. <i>Nutrition and Cancer</i> , 2016, 68, 750-755.	0.9	0
74	Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 164-171.	2.9	43
75	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 707-714.	1.2	8
76	Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability. <i>Nucleic Acids Research</i> , 2016, 44, 558-572.	6.5	18
77	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016, 19, 421-430.	2.7	11
78	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 597-606.	2.7	31
79	MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2508-2508.	0.8	21
80	Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4078-4078.	0.8	30
81	First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2597-TPS2597.	0.8	4
82	KEYNOTE-164: Phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3631-TPS3631.	0.8	4
83	More Accurate Prediction of Metastatic Pancreatic Cancer Patients's Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. <i>PLoS ONE</i> , 2016, 11, e0145692.	1.1	14
84	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. <i>PLoS ONE</i> , 2016, 11, e0151406.	1.1	15
85	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	0.8	93
86	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 28-36.	1.3	20
87	The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. <i>Cancer Research and Treatment</i> , 2016, 48, 171-179.	1.3	56
88	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1045-1055.	1.3	10
89	Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. <i>Cancer Research and Treatment</i> , 2016, 48, 990-997.	1.3	15
90	TTP or PFS as a surrogate endpoint in advanced hepatocellular carcinoma treated with systemic therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4075-4075.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Korean Cancer Patients's Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10067-10067.	0.8	0
92	Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. <i>Clinical Epigenetics</i> , 2015, 7, 63.	1.8	17
93	Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. <i>BMC Cancer</i> , 2015, 15, 690.	1.1	9
94	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. <i>BMC Cancer</i> , 2015, 15, 721.	1.1	19
95	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <i>Breast Cancer Research</i> , 2015, 17, 33.	2.2	138
96	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. <i>PLoS ONE</i> , 2015, 10, e0139749.	1.1	183
97	Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 790-795.	1.3	10
98	Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 1457.	1.4	98
99	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. <i>Oncologist</i> , 2015, 20, 926-933.	1.9	15
100	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2520-2529.	3.2	59
101	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 824-832.	2.7	91
102	Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System. <i>Materials</i> , 2015, 8, 519-534.	1.3	6
103	Identification of Long-Range Epigenetic Silencing on Chromosome 15q25 and Its Clinical Implication in Gastric Cancer. <i>American Journal of Pathology</i> , 2015, 185, 666-678.	1.9	6
104	Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 339-339.	0.8	7
105	Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0145004.	1.1	20
106	Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway. <i>World Journal of Gastroenterology</i> , 2015, 21, 9749.	1.4	24
107	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2015, 47, 607-615.	1.3	93
108	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 3376-88.	1.4	6

#	ARTICLE	IF	CITATIONS
109	Fabrication of biodegradable polymeric micro chambers encapsulated with pulverized drug for bacteria-based microrobots. , 2014, , .		0
110	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1224-1235.	5.1	1,932
111	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 1245-1253.	5.1	336
112	Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 767-774.	5.1	713
113	The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 13-25.	0.6	17
114	RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4058-4058.	0.8	7
115	ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1038-1038.	0.8	0
116	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. <i>Anticancer Research</i> , 2014, 34, 4275-80.	0.5	7
117	Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. <i>International Journal of Cancer</i> , 2013, 132, 2209-2216.	2.3	49
118	Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4121-4121.	0.8	6
119	Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2013, 45, 325-333.	1.3	49
120	Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 182-182.	0.8	0
121	The impact of diabetes mellitus and metformin on survival of patients with advanced pancreatic cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4044-4044.	0.8	3
122	The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15066-e15066.	0.8	0
123	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3076-3076.	0.8	6
124	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in previously treated advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 269-269.	0.8	2
125	Genetic polymorphisms and ethnic difference in outcome of adjuvant FOLFOX chemotherapy in Korean patients with colon cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 623-623.	0.8	0
126	Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3624-3624.	0.8	0

#	ARTICLE	IF	CITATIONS
127	The efficacy and toxicity of 3-weekly TS-1 containing chemotherapy in patients with unresectable advanced gastric cancer.. Journal of Clinical Oncology, 2012, 30, e14580-e14580.	0.8	0
128	Breast-conserving surgery after neoadjuvant chemotherapy for stage III breast cancer patients.. Journal of Clinical Oncology, 2012, 30, e11532-e11532.	0.8	0
129	STAT3 inhibits the degradation of HIF-1 α by pVHL-mediated ubiquitination. Experimental and Molecular Medicine, 2008, 40, 479.	3.2	103
130	Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells. Experimental and Molecular Medicine, 2008, 40, 639.	3.2	15
131	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Review of Molecular Diagnostics, 2007, 7, 821-836.	1.5	12
132	Histone Deacetylase Inhibitors for Cancer Therapy. Epigenetics, 2006, 1, 15-24.	1.3	61
133	A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus. The Korean Journal of Hematology, 2005, 40, 192.	0.7	0
134	A Phase III Randomized Trial of Combined Chemoradiotherapy Versus Radiotherapy Alone in Locally Advanced Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 238-243.	0.6	45
135	TGF- β 2 Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. Cancer Research and Treatment, 1970, 47, 101-109.	1.3	13